STIMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Neuronetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91+0.02 (+1.33%)
Close on Oct 19, 2026
- Market cap
- $139.68M
- P/E (TTM)
- –
- Dividend yield
- –
Neuronetics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Neuronetics | Industry median |
|---|---|---|
| Market Cap | $145.54M | $230.55M |
| Enterprise Value | $191.65M | $202.97M |
| PS Ratio | 0.94 | 3.11 |
| PB Ratio | 8.15 | 3.14 |
Enterprise value
| Measure | Neuronetics | Industry median |
|---|---|---|
| EV / Sales | 1.24 | 2.92 |
Income (trailing twelve months)
| Measure | Neuronetics | Industry median |
|---|---|---|
| Revenue | $155.10M | $102.39M |
| Gross Profit | $76.19M | $60.36M |
| Operating Income | -$22.86M | -$4.31M |
| Net Income | -$30.43M | -$6.57M |
| EBITDA | -$20.45M | -$1.98M |
| EPS (Diluted) | -$0.44 | -$0.07 |
Margins
| Measure | Neuronetics | Industry median |
|---|---|---|
| Gross Margin | 49.1% | 55.1% |
| Operating Margin | -14.7% | -6.04% |
| Profit Margin | -19.6% | -10.5% |
| EBITDA Margin | -13.2% | -2.67% |
| FCF Margin | -7.27% | -0.30% |
Returns
| Measure | Neuronetics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -135.3% | -19.2% |
| Return on Assets (ROA) | -22.9% | -13.3% |
| Return on Invested Capital (ROIC) | -27.4% | -4.11% |
| Return on Capital Employed (ROCE) | -22.1% | -9.07% |
Growth
| Measure | Neuronetics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 39.6% | 8.85% |
| Revenue Growth (3Y CAGR) | 31.8% | 7.08% |
| Revenue Growth (5Y CAGR) | 24.8% | 11.8% |
Balance sheet
| Measure | Neuronetics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $19.20M | $37.33M |
| Total Debt | $61.52M | $72.66M |
| Net Cash (Debt) | -$42.32M | $3.92M |
| Net Cash Per Share | -$0.56 | $0.28 |
| Equity (Book Value) | $17.85M | $57.36M |
| Book Value Per Share | $0.23 | $2.81 |
| Tangible Book Value | -$23.19M | $10.71M |
| Working Capital | $24.92M | $54.64M |
Financial position
| Measure | Neuronetics | Industry median |
|---|---|---|
| Current Ratio | 1.88 | 2.50 |
| Quick Ratio | 1.24 | 1.54 |
| Debt / Equity | 3.45 | 0.38 |
| Interest Coverage | -2.56 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Neuronetics | Industry median |
|---|---|---|
| Operating Cash Flow | -$10.33M | -$653.46K |
| Capital Expenditures | -$944.00K | -$3.69M |
| Free Cash Flow | -$11.28M | -$835.02K |
| FCF Per Share | -$0.15 | -$0.02 |
Efficiency
| Measure | Neuronetics | Industry median |
|---|---|---|
| Asset Turnover | 1.17 | 0.59 |
| Inventory Turnover | 15.11 | 2.21 |
| Revenue Per Employee | $235.71K | $322.57K |
| Profits Per Employee | -$46.25K | -$51.88K |
| Employee Count | 658 | 185 |
Dividends and yields
| Measure | Neuronetics | Industry median |
|---|---|---|
| Earnings Yield | -20.9% | -6.91% |
| FCF Yield | -7.75% | -0.56% |
Shares
| Measure | Neuronetics | Industry median |
|---|---|---|
| Shares Outstanding | 76,197,200 | 44,856,700 |
| Shares Change (YoY) | 42.9% | 3.35% |
| Shares Change (QoQ) | 9.50% | 0.27% |
| Float | 37,097,900 | 37,097,900 |
| Shares Held by Insiders | 51.3% | 10.6% |
| Shares Held by Institutions | 48.8% | 63.5% |
Scores
| Measure | Neuronetics | Industry median |
|---|---|---|
| Altman Z-Score | -3.41 | 1.95 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | -2.58 | -2.64 |
Calculated by StockData from Neuronetics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.